试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-25
A Clinical Trial to Assess the Safety, Tolerability and Immunogenicity of MenABCWY in Healthy Infants
编号:NCT04645966登记状态:提前终止企业 / 申办者:Pfizer
药物 / 成分:MenABCWY、Bivalent rLP2086 (60-µg Dose)、Bivalent rLP2086 (120-µg Dose)、Bexsero
登记的停止原因(原文):The Sponsor decided to discontinue the study based on Sponsor's careful review of available safety data in concert with the recommendation of an independent Data Monitoring Committee.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-25
SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma
编号:NCT04762160登记状态:提前终止企业 / 申办者:Epizyme, Inc.
药物 / 成分:Tazemetostat、Rituximab
登记的停止原因(原文):Decision to terminate EZH-1401 was solely due to company business decision.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-22
Pharmacokinetic Study of Intranasal Dexmedetomidine in Pediatric Patients With Congenital Heart Disease
编号:NCT03417999登记状态:提前终止企业 / 申办者:Children's Hospital of Philadelphia
药物 / 成分:Dexmedetomidine
登记的停止原因(原文):All subjects who were enrolled completed the study. However, the PI left the institution and the study was terminated before all cohorts were enrolled.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-22
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma
编号:NCT03571828登记状态:提前终止企业 / 申办者:Amgen
药物 / 成分:AMG 562
登记的停止原因(原文):Amgen decided to discontinue study because of a business decision and not because of safety reasons
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-22
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)
编号:NCT04113616登记状态:提前终止企业 / 申办者:Kartos Therapeutics, Inc.
药物 / 成分:KRT-232、Cytarabine、Decitabine
登记的停止原因(原文):In September 2023, the study was terminated because of a Sponsor decision, unrelated to safety concerns.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-22
A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
编号:NCT04682431登记状态:提前终止企业 / 申办者:Ikena Oncology
药物 / 成分:PY159 Single agent dose level 1、PY159 Single agent dose level 2、PY159 Single agent dose level 3、PY159 Single agent dose level 4
登记的停止原因(原文):Sponsor business decision.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-22
A Study of PY314 in Subjects With Advanced Solid Tumors
编号:NCT04691375登记状态:提前终止企业 / 申办者:Ikena Oncology
药物 / 成分:PY314、Combination Therapy: PY314 + Pembrolizumab
登记的停止原因(原文):Sponsor business decision.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-22
Safety and Bioactivity of AXT107 in Subjects With Diabetic Macular Edema
编号:NCT04697758登记状态:提前终止企业 / 申办者:AsclepiX Therapeutics, Inc.
药物 / 成分:AXT107 0.1 mg、AXT107 0.25 mg、AXT107 0.5 mg
登记的停止原因(原文):Adverse Events
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-22
Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration
编号:NCT04746963登记状态:提前终止企业 / 申办者:AsclepiX Therapeutics, Inc.
药物 / 成分:AXT107 0.1 mg、AXT107 0.25 mg、AXT107 0.5 mg
登记的停止原因(原文):Adverse Events
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-22
Erenumab-aooe for the Management of Trigeminal Neuropathic Pain.
编号:NCT05142228登记状态:提前终止企业 / 申办者:University of Maryland, Baltimore
药物 / 成分:Erenumab-Aooe、Placebo
登记的停止原因(原文):Low enrollment rate
查看官方原始记录 ↗